Article - BioPharm International

ADVERTISEMENT

Article

Process Validation: Using Tolerance Intervals for Setting Process Validation Acceptance Criteria

June 1, 2007

One goal of process characterization is establishing representative performance parameter ranges that can be used to set validation acceptance criteria (VAC). Characterization studies yield varying numbers of data points from multiple experiments, and may also include data generated at different scales (e.g., bench, pilot, and commercial), which add complexity to the analysis. Many statistical approaches can be used to set ranges from large data sets. As an example, we present the statistical considerations and techniques for setting validation acceptance ranges for a chromatography step used in purifying a recombinant protein. Performance parameter data from a combined data set consisting of 67 bench, six pilot, and three full-scale runs were analyzed using the statistical analysis software JMP (SAS Institute). The combined data set was used to compute tolerance intervals, so that sources such as scale and column feed material could be properly modeled. The resulting ranges were used to establish..

China Today: Biogenerics in China: An Evolving Industry

June 1, 2007

In China, the presence of a substantial biogenerics industry reflects a growing need to provide healthcare to domestic populations, at a reasonable cost.

Facility Design: Simulation Methodology for Facility Design

June 1, 2007

Discrete simulation allows the design teams to see every meaningful detail about equipment and materials flowing through the process.

Disposables: Biopharmaceutical Disposables as a Disruptive Future Technology

June 1, 2007

Today, most disposables are used for process development and clinical-scale manufacturing. Substantial growth in disposables usage may not occur until disposables are incorporated into the production of licensed products at commercial scale.

Final Word: Outsourcing in Today's Risk-Based Environment

June 1, 2007

Outsourcing has been a cornerstone of our industry for decades.

IP Briefs: The Positive Side of Negative Disclaimers

June 1, 2007

Addition of a disclaimer to a claim, based on words not present in the application as filed, is referred to as an undisclosed disclaimer.

FDA Moves to Streamline GMP Inspections

June 1, 2007

FDA's approach involves adopting efficient strategies for targeting inspections to more high-risk operations likely to have the greatest impact on public health.

Advances in Animal-Free Manufacturing of Biopharmaceuticals

May 2, 2007

In addition to existing guidance, in January 2007 the FDA announced further proposals to prohibit the use of certain bovine materials as ingredients in some medical products or as elements of product manufacturing.

Rapid High-Throughput Feed Optimization

May 2, 2007

Growth of CHO cell cultures in a shaker plate model system was demonstrated to be comparable to growth in shake flasks.

ADVERTISEMENT

ADVERTISEMENT

Click here